Press releaseBusiness Wire
ARS Pharmaceuticals
SPRY · NASDAQ
$4.29+$0.06 (+1.42%)TodayMarket closed ·
Prev close $4.23
Latest news
- Press releasePRNewswire
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
- Press releaseNewsfile
Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026
- Press releasePRNewswire
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
- Press releasePRNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
- Press releaseNewsfile
Kaplan Fox Notifies Investors: Deadline to Lead in the ARS Pharmaceuticals Inc. (SPRY) Securities Class Action is October 5, 2026
- Press releaseGlobe Newswire
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
- Press releaseGlobe Newswire
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors
- Press releasePRNewswire
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
- Press releaseGlobe Newswire
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
- Press releaseGlobe Newswire
Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.
- Press releaseNewsfile
Kaplan Fox Alerts Investors of ARS Pharmaceuticals Inc. (SPRY) to an Upcoming Deadline of October 5, 2026 in the Securities Class Action
- Press releaseGlobe Newswire
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
- Press releaseGlobe Newswire
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
- Press releaseNewsfile
Kaplan Fox Notifies ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Lawsuit - Deadline is October 5, 2026
- Press releasePRNewswire
SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact SueWallSt
- Press releasePRNewswire
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
- Press releaseNewsfile
Kaplan Fox Announces a Securities Class Action Against ARS Pharmaceuticals Inc. (SPRY) - Lead Plaintiff Deadline is October 5, 2026
- Press releasePRNewswire
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action Notice - Contact Levi & Korsinsky
- Press releaseGlobe Newswire
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026
- Press releaseNewsfile
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (SPRY) to Act Ahead of the Lead Plaintiff Deadline on October 5, 2026
- Press releasePRNewswire
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
- Press releasePRNewswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
- Press releasePRNewswire
SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline
- Press releasePRNewswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
- Press releaseGlobe Newswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
- Press releaseGlobe Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
- Press releasePRNewswire
SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
- Press releasePRNewswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
- Press releaseGlobe Newswire
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
- Press releasePRNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
- Press releasePRNewswire
Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
- NewsVandana Singh
Can ARS Pharma's New CEO Unlock Neffy's Potential?
- Press releaseGlobe Newswire
ARS Pharmaceuticals Announces CEO Succession
- NewsVandana Singh
ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins
- NewsAvi Kapoor
Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High
- NewsTanya Rawat
ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage
- Press releaseGlobe Newswire
ARS Pharmaceuticals Provides Commercial and Financial Updates
- Press releaseGlobe Newswire
Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
- Press releaseGlobe Newswire
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
- Press releaseGlobe Newswire
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
- News
Health Canada Approves ARS Pharmaceuticals' Neffy 2 Mg (Epinephrine Nasal Spray) For The Emergency Treatment Of Allergic Reactions (Anaphylaxis) In Adults And Children Who Weigh 30 kg Or More
- Press releaseGlobe Newswire
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
- Press releaseGlobe Newswire
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
- Press releaseGlobe Newswire
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.